
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Tela Bio Inc (TELA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TELA (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $5.4
1 Year Target Price $5.4
3 | Strong Buy |
1 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.15% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 63.39M USD | Price to earnings Ratio - | 1Y Target Price 5.4 |
Price to earnings Ratio - | 1Y Target Price 5.4 | ||
Volume (30-day avg) 5 | Beta 0.93 | 52 Weeks Range 0.86 - 3.26 | Updated Date 08/15/2025 |
52 Weeks Range 0.86 - 3.26 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.18 | Actual -0.22 |
Profitability
Profit Margin -54.12% | Operating Margin (TTM) -44.96% |
Management Effectiveness
Return on Assets (TTM) -36.47% | Return on Equity (TTM) -676.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 70311304 | Price to Sales(TTM) 0.84 |
Enterprise Value 70311304 | Price to Sales(TTM) 0.84 | ||
Enterprise Value to Revenue 0.93 | Enterprise Value to EBITDA -5.01 | Shares Outstanding 39616400 | Shares Floating 18693017 |
Shares Outstanding 39616400 | Shares Floating 18693017 | ||
Percent Insiders 8.3 | Percent Institutions 74.2 |
Upturn AI SWOT
Tela Bio Inc

Company Overview
History and Background
Tela Bio, Inc. was founded in 2012 and is focused on developing and marketing regenerative tissue matrix products for soft tissue reconstruction. The company has grown through product development and commercialization of its OviTex and reinforced brands.
Core Business Areas
- Surgical Reconstruction: This segment develops and sells surgical mesh products for hernia repair and abdominal wall reconstruction. Their OviTex Reinforced Tissue Matrix is a key product in this segment.
- Reconstructive and Plastic Surgery: Offers products for breast reconstruction and other plastic surgery procedures, utilizing regenerative tissue matrix technology.
Leadership and Structure
Tela Bio is led by Antony Koblish as President and CEO. The company has a typical corporate structure with departments for R&D, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- OviTex Reinforced Tissue Matrix: OviTex is a reinforced tissue matrix used in hernia repair and abdominal wall reconstruction. While precise market share data is variable and depends on the specific sub-segment, Tela Bio is a significant player in the biosurgical mesh market. Competitors include BD (Becton Dickinson - BDX), Medtronic (MDT), and W.L. Gore & Associates.
- Reinforced Brands (OviTex PRS, etc.): This is a range of reinforced brands which are variants of OviTex. Market share data and competitors are generally the same as OviTex but it serves the breast reconstruction market.
Market Dynamics
Industry Overview
The surgical mesh and regenerative medicine market is growing due to an aging population, increasing surgical procedures, and technological advancements. Key trends include minimally invasive surgery and the use of biologic materials.
Positioning
Tela Bio is positioned as an innovator in regenerative tissue matrices, focusing on improved patient outcomes and reduced complications compared to synthetic meshes. Their competitive advantage lies in their patented OviTex technology.
Total Addressable Market (TAM)
The global surgical mesh market is estimated to be billions of dollars. Tela Bio's positioning allows it to capture a growing share of this market, particularly in the biologic and reinforced mesh segments. Specific TAM estimates vary depending on the source and market definition.
Upturn SWOT Analysis
Strengths
- Proprietary OviTex technology
- Focus on regenerative medicine
- Growing revenue and market share
- Strong sales force dedicated to their field
Weaknesses
- Reliance on a limited number of products
- Need for continued innovation to maintain competitive edge
- High marketing costs for market penetration
Opportunities
- Expansion into new geographic markets
- Development of new applications for OviTex technology
- Strategic partnerships and acquisitions
- Increase in the number of surgical procedures
Threats
- Competition from larger medical device companies
- Regulatory changes and increased scrutiny
- Product liability lawsuits
- Price pressures from healthcare providers
Competitors and Market Share
Key Competitors
- BDX
- MDT
- SYK
Competitive Landscape
Tela Bio's advantages include its proprietary technology and focus on regenerative medicine. Disadvantages include its smaller size and limited product portfolio compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Tela Bio has experienced significant revenue growth in recent years due to increased adoption of OviTex and reinforced brands.
Future Projections: Analysts expect continued revenue growth for Tela Bio, driven by expansion into new markets and product development. Profitability is expected to improve as the company scales.
Recent Initiatives: Recent initiatives include expanding the sales force, launching new OviTex products and entering new markets.
Summary
Tela Bio is a company with promising growth based on its regenerative medicine products, particularly OviTex. Its smaller size compared to its peers poses a potential risk. Successful market penetration and innovation will be key. Regulatory landscape and economic fluctuations require a cautious outlook.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and may vary depending on the source. Please do your own research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tela Bio Inc
Exchange NASDAQ | Headquaters Malvern, PA, United States | ||
IPO Launch date 2019-11-08 | Co-founder, CEO & Director Mr. Antony Koblish | ||
Sector Healthcare | Industry Medical Devices | Full time employees 209 | Website https://www.telabio.com |
Full time employees 209 | Website https://www.telabio.com |
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.